
Feature|Articles|February 27, 2025
The Rapid Evolution of Multiple Myeloma Treatment in Recent Years
Author(s)Kyle Doherty
Fact checked by: Caroline Seymour
Multiple myeloma experts offer their perspectives on the evolution of the treatment landscape over the past 10 years and look towards the future of care.
Advertisement
Advertisement
Multiple myeloma, once considered a disease with a poor prognosis, has experienced a revolution in treatment over the past decade with the emergence of new approaches, such as CAR T-cell therapy and bispecific T-cell engagers. As other novel therapies progress through the development pipeline, investigators will have to consider a variety of patient-specific factors when selecting and sequencing treatments, but the future of the field is bright.
Related to this article

The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.

The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

An OncLive Scientific Interchange and Workshop covered sequencing, toxicity management, and access barriers for CAR T-cell therapy in multiple myeloma.

Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.

The FDA accepted a new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed/refractory multiple myeloma.
Advertisement
Advertisement


